Allogene Therapeutics (ALLO) News Today $1.90 -0.17 (-8.21%) (As of 05:11 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from BrokeragesDecember 18 at 2:41 AM | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by AnalystsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issuedDecember 18 at 2:39 AM | marketbeat.comAllogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 16 at 8:30 AM | globenewswire.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest UpdateAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 31,170,000 shares, a decrease of 11.1% from the November 15th total of 35,050,000 shares. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 13.8 days.December 15 at 7:21 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) & Kodiak Sciences (NASDAQ:KOD) Head-To-Head ComparisonDecember 15 at 1:43 AM | americanbankingnews.comAllogene acknowledges passing of founding board member David BondermanDecember 13, 2024 | markets.businessinsider.comAllogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanDecember 12, 2024 | globenewswire.comPiper Sandler Remains a Buy on Allogene Therapeutics (ALLO)December 11, 2024 | markets.businessinsider.comDeborah M. Messemer Sells 9,136 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) StockDecember 11, 2024 | insidertrades.com516,601 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Acquired by Zacks Investment ManagementZacks Investment Management purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 516,601 shares of the company's stock, valued at approxDecember 10, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Director Franz B. Humer Sells 9,221 SharesDecember 10, 2024 | insidertrades.comFmr LLC Cuts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Fmr LLC cut its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,026,956 shares of the company's stock afterDecember 6, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Down 5.4% in NovemberAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 35,050,000 shares, a drop of 5.4% from the October 31st total of 37,040,000 shares. Based on an average daily volume of 2,160,000 shares, the days-to-cover ratio is presently 16.2 days.December 3, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vestal Point Capital LPVestal Point Capital LP lowered its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 31.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,500,000 shares ofNovember 29, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendatiNovember 23, 2024 | marketbeat.comCautious Hold Rating for Allogene Therapeutics Amid Promising Preclinical Data and Intense CompetitionNovember 21, 2024 | markets.businessinsider.comAllogene Therapeutics presents data for ALLO-329 in autoimmune diseaseNovember 19, 2024 | markets.businessinsider.comAllogene Therapeutics Announces Participation in December Investor ConferencesNovember 19, 2024 | globenewswire.comAllogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceNovember 18, 2024 | globenewswire.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Decrease in Short InterestAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 37,040,000 shares, a drop of 5.8% from the October 15th total of 39,320,000 shares. Approximately 26.7% of the shares of the company are sold short. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is currently 18.7 days.November 18, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)November 14, 2024 | markets.businessinsider.comAllogene Therapeutics price target lowered to $9 from $11 at Piper SandlerNovember 14, 2024 | markets.businessinsider.comStrategic Resource Reallocation and Growth Focus Underpin Buy Rating for Allogene TherapeuticsNovember 14, 2024 | markets.businessinsider.comAllogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst DowngradeAllogene Therapeutics (NASDAQ:ALLO) Trading Down 6.3% on Analyst DowngradeNovember 14, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Given New $9.00 Price Target at Piper SandlerPiper Sandler decreased their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday.November 14, 2024 | marketbeat.comStifel Nicolaus Sticks to Its Hold Rating for Allogene Therapeutics (ALLO)November 13, 2024 | markets.businessinsider.comJMP Securities Remains a Hold on Allogene Therapeutics (ALLO)November 11, 2024 | markets.businessinsider.comAllogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Allogene Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)November 8, 2024 | markets.businessinsider.comAllogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...November 8, 2024 | finance.yahoo.comPromising Efficacy and Strategic Advancements Propel Allogene Therapeutics to a Buy RatingNovember 8, 2024 | markets.businessinsider.comAllogene Therapeutics’ Promising Clinical Trial Advances and Strategic Positioning: A Buy Recommendation by Tyler Van BurenNovember 8, 2024 | markets.businessinsider.comAllogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comAllogene Therapeutics Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comAllogene announces Phase 1 data on ALLO-316 in advanced RCCNovember 7, 2024 | markets.businessinsider.comAllogene Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateNovember 7, 2024 | markets.businessinsider.comAllogene Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateNovember 7, 2024 | globenewswire.comAllogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCSNovember 7, 2024 | globenewswire.comAllogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comAllogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetingsNovember 5, 2024 | markets.businessinsider.comAllogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 5, 2024 | globenewswire.comAllogene Therapeutics (NASDAQ:ALLO) Trading 6.3% Higher - Time to Buy?Allogene Therapeutics (NASDAQ:ALLO) Trading 6.3% Higher - Here's What HappenedNovember 4, 2024 | marketbeat.comAllogene Therapeutics (ALLO) Set to Announce Earnings on ThursdayAllogene Therapeutics (NASDAQ:ALLO) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.October 31, 2024 | marketbeat.comAllogene Therapeutics' (ALLO) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research report on Wednesday.October 30, 2024 | marketbeat.comAllogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business UpdateOctober 30, 2024 | globenewswire.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating oOctober 29, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6% - Time to Buy?Allogene Therapeutics (NASDAQ:ALLO) Shares Up 6.6% - Here's WhyOctober 28, 2024 | marketbeat.comRefractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 28, 2024 | theglobeandmail.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.4% - What's Next?Allogene Therapeutics (NASDAQ:ALLO) Trading Down 5.4% - Time to Sell?October 24, 2024 | marketbeat.comZacks Research Issues Optimistic Forecast for ALLO EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities researchers at Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a research note issued on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts thatOctober 24, 2024 | marketbeat.com Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. ALLO Media Mentions By Week ALLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.540.56▲Average Medical News Sentiment ALLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼94▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NMRA News Today BCRX News Today NVAX News Today IMCR News Today MESO News Today BLUE News Today VIR News Today ADPT News Today PSTX News Today IMTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
